Skip to main content

Table 3 Antiviral treatment

From: Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

  Received treatment (N = 18) Untreated (N = 11)
Media age (IQR)—years 47.5 (45–55.7) 39 (35–53)
Female sex—n (%) 13 (72.2%) 5 (45.4%)
Covid-19 pneumonia—n (%) 11 (61.1%) 4 (36.3%)
Covid-19 severity—n (%)   
 Mild 5 (27.7%) 2 (18.1%)
 Moderate 4 (22.2%) 2 (18.1%)
 Severe 9 (50%) 7 (63.6%)
COVID-19 acute antiviral treatment—n (%) 13 (72.2%) 6 (54.5%)
Positive results of plasma PCR—n (%) 9 (50%) 4 (36%)
At least one positive PCR—n (%) 10 (55.5%) 5 (45.4%)
Basal functional status   
 Grade 0—n (%) 0 (0%) 0 (0%)
 Grade I—n (%) 1 (5.5%) 6 (54.54%)
 Grade II—n (%) 5 (27.7%) 3 (27.27%)
 Grade III—n (%) 4 (22.2%) 1 (9%)
 Grade IV—n (%) 8 (44.4%) 1 (9%)
  1. n  number